Search

Objectives: To date, studies have not provided definitive answers regarding whether previous immune checkpoint inhibitor (ICI) treatment alters outcomes for cancer patients with COVID-19. Methods: The OnCovid registry (NCT04393974) was searched from February 27, 2020, to January 31, 2022, for patients who received systemic anti-cancer therapy in the 4 weeks before laboratory-confirmed COVID-19 diagnosis. Propensity-score matching using country, vaccination status, primary tumor type, sex, age, comorbidity burden, tumor stage, and remission status investigated differences in predefined clinical outcomes comparing those who had or had not received ICIs. Results: Of 3523 patients screened, 137 ICI-only and 1378 non-ICI met inclusion criteria. Before matching, ICI patients were older, male, enrolled at centers in Italy, and had histories of smoking, thoracic cancers, advanced cancer stages, and active malignancies (P ≤0.02). After matching, there were 120 ICI and 322 non-ICI patients. ICI patients had no differences (odds ratio: 95% CI) in presenting COVID-19 symptoms (0.69: 0.37-1.28), receipt of COVID-specific therapy (0.88: 0.54-1.41), 14-day (0.95: 0.56-1.61), or 28-day (0.79: 0.48-1.29) mortalities. However, ICI patients required less COVID-19-related hospitalization (0.37: 0.21-0.67) and oxygen therapy (0.51: 0.31-0.83) and developed fewer complications (0.57: 0.36-0.92). Conclusion: In this propensity-score matched analysis, previous ICI therapy did not worsen and potentially improved COVID-19 outcomes in patients with cancer.

Products that activate plant defense mechanisms, such as white mold, may increase the disease control spectrum in canola crops as an alternative to chemical control for disease management, aiming at lower environmental impacts and selection pressure on pathogens. This study evaluated Sclerotinia sclerotiorum control and resistance induction in canola crops with alternative products. In vitro and detached leaf experiments were conducted in a laboratory, and in vivo experiments occurred in a greenhouse. High Roots®; V6®; Maxi Flor®; Wert Plus®; potassium, manganese, and copper phosphites; manganese; procymidone fungicide; and Ascophyllum nodosum, Bacillus subtilis, and Bacillus thuringiensis extracts assessed S. sclerotiorum mycelial growth in vitro in detached leaves, white mold severity in a greenhouse, and enzymatic analysis in leaf tissues. The last two experiments also received the acibenzolar-S-methyl and Trichoderma asperellum treatments. S. sclerotiorum mycelial growth showed 100% inhibition under B. subtilis and Wert Plus® at 1000 ppm and procymidone at 100 and 1000 ppm in vitro. The procymidone and B. subtilis treatments in detached leaves inhibited 100% of fungus growth. The greenhouse experiments with lower severity were procymidone, copper phosphite, B. thuringiensis, B. subtilis, manganese phosphite, potassium phosphite, High Roots®, and V6®. Higher peroxidase enzyme activity occurred in plants treated with acibenzolar-S-methyl, copper phosphite, and fungicide 48 hours after pathogen inoculation. The polyphenol oxidase enzyme did not show activity. Alternative products were responsive and may aid the chemical control of white mold in canola crops.

Copyright of Movement & Sport Sciences / Science & Motricité is the property of EDP Sciences and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

• This EHA–ESMO Clinical Practice Guideline provides key recommendations for managing HIV-associated lymphomas. • The guideline covers clinical, imaging and pathological diagnosis; staging and risk assessment; treatment and follow-up. • The author group encompasses a multidisciplinary group of experts from different institutions and countries in Europe. • Recommendations are based on available scientific data and the authors' collective expert opinion. [ABSTRACT FROM AUTHOR]